Infliximab vs adalimumab for Crohn's disease: perhaps too early to call it a tie

Clin Gastroenterol Hepatol. 2014 May;12(5):818-20. doi: 10.1016/j.cgh.2013.12.006. Epub 2013 Dec 14.

Authors

Themistocles Dassopoulos¹, Dario Sorrentino²

Affiliations

¹ IBD Center, Division of Gastroenterology, Washington University in St Louis, St Louis, Missouri.
² IBD Center, Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, Virginia; Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy.

PMID: 24342747
DOI: 10.1016/j.cgh.2013.12.006

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Crohn Disease / drug therapy*
Female
Gastrointestinal Agents / therapeutic use*
Humans
Immunologic Factors / therapeutic use*
Male

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
Immunologic Factors